Online citations, reference lists, and bibliographies.
← Back to Search

Emerging Immunotherapy For The Treatment Of Esophageal Cancer

SeungJu Jackie Oh, Songhee Han, W. Lee, A. Lockhart
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Introduction: Esophageal cancer is the third most common cancer of the gastrointestinal tract. Despite new therapies, the prognosis for patients with these cancers remains poor with 5-year survival rates lower than 15%. Recently, immunotherapy has increasingly gained attention as a novel treatment strategy for advanced esophageal cancer. Areas covered: Recent success of immunotherapy in treating other solid tumors has shed light on the utility of these approaches for esophageal cancers. Here, the authors focus on antibody-based, adoptive-cell-therapy-based, and vaccine-based immunotherapies, and briefly address their rationale, clinical data, and implications. Expert opinion: Immunotherapy is now established to be a key treatment modality that can improve the outcomes of many cancer patients and appears to be ushering in a new era in cancer treatment. Checkpoint inhibitor drugs have shown preliminary favorable results in esophageal cancer treatment. Adoptive cell therapy and vaccine studies have also shown some promise in various clinical studies. Future endeavors will need to focus on identifying patients who are likely to benefit from immunotherapy, monitoring and managing immune responses and designing optimal combination strategies where immunotherapy agents are combined with other traditional treatment modalities.
This paper references
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.
S. Hannier (1998)
10.1056/NEJMoa1510665
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
R. Motzer (2015)
10.1111/j.1349-7006.2010.01732.x
Vaccination with peptides derived from cancer‐testis antigens in combination with CpG‐7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma
M. Iwahashi (2010)
Radiation-induced tumor neoantigens: imaging and therapeutic implications.
C. Corso (2011)
Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial.
K. Kono (2002)
Lymphokine activated killer cells: a new approach to immunotherapy of cancer.
G. Semenzato (1990)
10.1016/S0140-6736(13)61719-5
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
C. Fuchs (2014)
Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology
JH Rubenstein (2015)
10.1056/NEJMoa1501824
Pembrolizumab for the treatment of non-small-cell lung cancer.
E. Garon (2015)
10.1186/1479-5876-10-236
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
A. Ribas (2012)
10.1038/modpathol.3800712
Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus
U. Reichelt (2007)
10.1186/1479-5876-10-141
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
K. Kono (2012)
10.1016/J.YONC.2012.05.013
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
E. Chiorean (2012)
10.1053/j.gastro.2015.04.053
Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma.
J. Rubenstein (2015)
10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M
Estimates of the worldwide mortality from 25 cancers in 1990
P. Pisani (1999)
10.1186/s13045-015-0185-6
Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade
G. Goel (2015)
10.1007/s00262-014-1521-3
Monitoring the immune competence of cancer patients to predict outcome
Serena Chang (2014)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1002/ijc.23810
Analysis of peripheral and local anti‐tumor immune response in esophageal cancer patients after NY‐ESO‐1 protein vaccination
H. Wada (2008)
10.1158/1078-0432.CCR-06-1772
Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer
N. Nesslinger (2007)
10.1093/annonc/mds263
Evolution of end points for cancer immunotherapy trials.
A. Hoos (2012)
This was the first report of a positive phase 3 trial demonstrating therapeutic benefits with HER2-targeted therapy in gastric and gastroesophageal junction cancers
10.1006/GENO.1994.1562
Structure and chromosomal localization of the human PD-1 gene (PDCD1).
T. Shinohara (1994)
10.1200/JCO.2011.36.2236
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
A. Ohtsu (2011)
10.1158/0008-5472.CAN-04-1525
Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes
C. T. Garnett (2004)
10.1002/eji.200323382
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
C. Workman (2003)
10.18632/oncotarget.6113
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies
S. Gebremeskel (2015)
10.1038/onc.2009.356
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesnière (2010)
10.1016/J.IT.2003.10.001
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.
F. Triebel (2003)
10.1084/JEM.182.2.459
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
10.1259/0007-1285-48-574-863
An interesting case of possible abscopal effect in malignant melanoma.
D. Kingsley (1975)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1038/nm1100
Cancer immunotherapy: moving beyond current vaccines
S. Rosenberg (2004)
• A very informative review on the recent advances with immune checkpoint inhibitors
10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
10.1001/archdermatol.2011.176
Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity.
Shane E. Cotter (2011)
10.1097/CJI.0000000000000017
Vaccination With NY-ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY-ESO-1 Antigen
H. Wada (2014)
10.1016/S1470-2045(14)70420-6
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
H. Wilke (2014)
10.1038/nrd2241
Development trends for monoclonal antibody cancer therapeutics
J. Reichert (2007)
10.1084/JEM.171.5.1393
LAG-3, a novel lymphocyte activation gene closely related to CD4
F. Triebel (1990)
10.1056/NEJMoa1412082
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
10.1111/dote.12147
Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).
L. Mathieu (2014)
10.1136/gut.43.4.575
Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis
K. Ohba (1998)
10.1007/s10120-014-0402-y
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
E. Van Cutsem (2014)
10.1016/j.gtc.2008.09.012
Esophageal cancer.
P. Siersema (2008)
2012 Landes Bioscience. Do not distribute. Abscopal but desirable The contribution of immune responses to the efficacy of radiotherapy
G. Kroemer (2012)
10.1016/j.ejca.2014.01.009
Targeted therapies in gastroesophageal cancer.
S. Kasper (2014)
Cancer immunology
OJ Finn (2008)
10.1155/2014/794249
The Intensity of Radiotherapy-Elicited Immune Response Is Associated with Esophageal Cancer Clearance
Jin-lu Ma (2014)
10.1111/j.1349-7006.2009.01200.x
Vaccination with multiple peptides derived from novel cancer‐testis antigens can induce specific T‐cell responses and clinical responses in advanced esophageal cancer
K. Kono (2009)
10.1002/(SICI)1097-0215(19991210)83:6<870::AID-IJC35>3.0.CO;2-9
Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999).
P. Pisani (1999)
10.1136/gutjnl-2014-308124
Global incidence of oesophageal cancer by histological subtype in 2012
M. Arnold (2014)
10.1158/1078-0432.CCR-09-2870
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
C. Ralph (2010)
In vivo antitumor activity of anti-CD3-induced activated killer cells.
Y. Yun (1989)
10.1186/1479-5876-11-246
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
S. Kageyama (2013)
10.1016/S0009-9260(81)80310-8
Abscopal regression in lymphoma: a mechanism in common with total body irradiation?
G. Rees (1981)
10.1097/CJI.0b013e318163628c
Mechanisms Involved in Radiation Enhancement of Intratumoral Dendritic Cell Therapy
S. Teitz-Tennenbaum (2008)
Age and sex differences in the incidence of esophageal adenocarcinoma: results from the surveillance, epidemiology, and end results (SEER) registry (19732008)
LN Mathieu (2014)
10.1007/s101470200058
Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer
U. Toh (2002)
10.1056/NEJMoa1112824
Immunologic correlates of the abscopal effect in a patient with melanoma.
M. Postow (2012)
10.4161/cbt.12.3.15949
Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy
M. Forghanifard (2011)
10.1056/NEJM198512053132327
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
S. Rosenberg (1985)
10.1177/1078155214538087
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
J. Lu (2015)
10.1200/JCO.2005.00.240
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
M. Dudley (2005)
10.1158/1078-0432.CCR-04-1469
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Yuichiro Ohigashi (2005)
This was the pivotal study showing that ipilimumab extends the OS of metastatic melanoma patients, and these results provided key data for the FDA approval of ipilimumab as the first-in-class drug
(2011)
• A report on the preliminary results from a phase 1 trial that showed promising safety and efficacy profiles of the PD-1 inhibitor pembrolizumab in patients with PD-L1-positive esophageal cancers
10.1016/j.coi.2011.01.003
Cancer immunology.
C. J. Melief (2011)
10.1517/14728214.2015.983072
Emerging mAbs for the treatment of esophagogastric cancer
G. Ku (2015)
10.1002/ijc.25955
A phase I study of vaccination with NY‐ESO‐1f peptide mixed with Picibanil OK‐432 and Montanide ISA‐51 in patients with cancers expressing the NY‐ESO‐1 antigen
K. Kakimi (2011)
10.1016/S0140-6736(10)61121-X
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Y. Bang (2010)
10.1002/IJC.2910540209
Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas
M. Al-kasspooles (1993)
10.1038/74704
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
R. Clynes (2000)
Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in EXPERT OPINION ON INVESTIGATIONAL DRUGS 675 advanced gastric and esophageal adenocarcinoma
C Ralph (2010)
10.1007/s00262-013-1508-5
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
C. Meyer (2013)
Locoregional cellular immunotherapy for patients with advanced esophageal cancer.
U. Toh (2000)
10.1259/0007-1285-56-661-63
Abscopal regression following radiotherapy for adenocarcinoma.
G. Rees (1983)
10.1158/1078-0432.CCR-07-4485
Enhancement of Antitumor Radiation Efficacy and Consistent Induction of the Abscopal Effect in Mice by ECI301, an Active Variant of Macrophage Inflammatory Protein-1α
K. Shiraishi (2008)
10.1097/PPO.0000000000000154
Tumor-Infiltrating Lymphocytes: Clinical Experience.
M. Besser (2015)
Update on phase III clinical trial of investigational MAGEA3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GS Kline (2014)
10.1038/nrc2355
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
S. Rosenberg (2008)
This was a major phase 3 trial that led to the FDA approval of nivolumab for advanced squamous non-small cell lung cancer
Tremelimumab for patients with chemotherapyresistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
L Calabro (2013)
10.1126/SCIENCE.1079490
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
S. Hori (2003)
10.4081/ejh.2011.e7
MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
T. Bujas (2011)
10.1111/j.1365-2567.2005.02145.x
The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells
L. Maçon-Lemaître (2005)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
M. S. Lawrence (2013)
10.1007/s13277-015-3426-y
Circulating CD14+HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC
Haitao Huang (2015)
10.1016/j.vaccine.2014.09.002
High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
T. Saito (2014)
10.1038/nrclinonc.2011.45
Targeting the human EGFR family in esophagogastric cancer
A. Okines (2011)
10.1158/1078-0432.CCR-09-0265
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody
M. Z. Dewan (2009)
10.1016/S1470-2045(13)70096-2
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
T. Waddell (2013)
10.3892/IJO.31.3.509
Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice.
Y. Akutsu (2007)
10.1158/2326-6066.CIR-15-0046
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
S. Derks (2015)
Dose-dependent effects of NYESO-1 protein vaccine complexed with cholesteryl pullulan (CHPNY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
S Kageyama (2013)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1097/CJI.0b013e3182619cb4
Clinical Trial of the Intratumoral Administration of Labeled DC Combined With Systemic Chemotherapy for Esophageal Cancer
Shinichi Fujiwara (2012)
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
A. Uenaka (2007)
10.1016/S1470-2045(13)70136-0
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
T. Crosby (2013)
10.1084/JEM.161.1.72
Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease
S. Sakaguchi (1985)
10.4049/jimmunol.175.9.6169
Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma
S. Rosenberg (2005)
10.1200/JCO.2010.28.9793
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
J. Brody (2010)
10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
10.3109/14653249.2012.681038
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol.
S. Rutella (2012)
10.1126/SCIENCE.3489291
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
S. Rosenberg (1986)
10.1158/1078-0432.CCR-07-4462
T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy
D. Schaue (2008)
10.1038/nature13480
Comprehensive molecular characterization of gastric adenocarcinoma
A. Bass (2014)



This paper is referenced by
10.21037/TCR.2016.06.30
A Promising Road in Colorectal Cancer Treatment: Personalized Immunotherapy Based on Molecular and Immune Classification System
Seungju Oh (2016)
10.2217/bmm-2019-0294
Prognostic significance of C-MYC dysregulation in esophageal squamous cell carcinoma: a meta-analysis.
X. Shi (2020)
10.21037/acs.2017.02.01
Future directions in esophageal cancer therapy.
Ori Wald (2017)
10.1016/j.clineuro.2020.106071
Clinical characteristics and surgical treatment of esophageal cancer spinal metastasis – A single center 10-year retrospective study
Xi Zhou (2020)
10.3390/ijms21010258
Emerging Role of Non-Coding RNAs in Esophageal Squamous Cell Carcinoma
Qingqing Feng (2019)
10.1371/journal.pone.0216759
The ginsenoside Rk3 exerts anti-esophageal cancer activity in vitro and in vivo by mediating apoptosis and autophagy through regulation of the PI3K/Akt/mTOR pathway
H. Liu (2019)
10.1007/978-3-319-91830-3_8
Anesthetic Concerns for Esophageal Surgery
J. Jackson (2018)
Novelties in immunotherapy of esophageal and stomach cancer
V. Bišof (2017)
10.1111/1759-7714.13537
Characterization of gene expression profiles of esophageal cancer patients with different nonsynonymous tumor mutation burden
Jia-wei Li (2020)
10.7759/cureus.3089
Abscopal Effect after Palliative Radiation Therapy for Metastatic Adenocarcinoma of the Esophagus
Moss Bruton Joe (2018)
10.1039/c9ra07830d
Panax notoginseng saponins regulate VEGF to suppress esophageal squamous cell carcinoma progression via DVL3-mediated Wnt/β-catenin signaling
Chen Xiaoqi (2020)
10.1016/j.ejpb.2017.03.013
Nanoparticles for tumor immunotherapy
Xinlong Zang (2017)
10.1016/j.biopha.2018.04.088
The potential of herb medicines in the treatment of esophageal cancer.
J. Ying (2018)
10.1080/01635581.2019.1677925
The prognostic value of modified Glasgow prognostic score in patients with esophageal squamous cell cancer: a Meta-analysis
Yan Wang (2019)
10.3892/ol.2017.7188
T-cell immunoglobulin and mucin domain-containing protein-3 and galectin-9 protein expression: Potential prognostic significance in esophageal squamous cell carcinoma for Chinese patients
N. Hou (2017)
Semantic Scholar Logo Some data provided by SemanticScholar